MCID: FNC012
MIFTS: 31

Functioning Pancreatic Endocrine Tumor malady

Categories: Rare diseases, Endocrine diseases

Aliases & Classifications for Functioning Pancreatic Endocrine Tumor

Aliases & Descriptions for Functioning Pancreatic Endocrine Tumor:

Name: Functioning Pancreatic Endocrine Tumor 50

Classifications:



Summaries for Functioning Pancreatic Endocrine Tumor

MalaCards based summary : Functioning Pancreatic Endocrine Tumor is related to non-functioning pancreatic endocrine tumor and childhood kidney cell carcinoma. An important gene associated with Functioning Pancreatic Endocrine Tumor is NEUROG3 (Neurogenin 3), and among its related pathways/superpathways are Mesodermal Commitment Pathway and Regulation of beta-cell development. The drugs Pancrelipase and pancreatin have been mentioned in the context of this disorder. Related phenotypes are behavior/neurological and cellular

Related Diseases for Functioning Pancreatic Endocrine Tumor

Diseases related to Functioning Pancreatic Endocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Related Disease Score Top Affiliating Genes
1 non-functioning pancreatic endocrine tumor 12.4
2 childhood kidney cell carcinoma 10.3 POU5F1 SOX2
3 pediatric liposarcoma 10.3 POU5F1 SOX2
4 kidney disease 10.3 POU5F1 SYP
5 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 6 10.3 CHGA NEUROG3
6 peroneal nerve paralysis 10.3 CHGA SYP
7 thymus small cell carcinoma 10.3 CHGA SYP
8 brain stem ependymoma 10.3 CHGA SYP
9 non specific chronic endometritis 10.3 CHGA SYP
10 extrahepatic biliary papillomatosis 10.3 CHGA SYP
11 prolactin producing pituitary tumor 10.3 CHGA SYP
12 epithelioid malignant peripheral nerve sheath tumor 10.3 CHGA SYP
13 cartilage cancer 10.3 CHGA SYP
14 villous adenocarcinoma 10.3 CHGA SYP
15 jejunal neuroendocrine tumor 10.3 CHGA SYP
16 renal pelvis adenocarcinoma 10.2 CHGA SYP
17 spasmodic dysphonia 10.2 CHGA SYP
18 barre-lieou syndrome 10.2 CHGA SYP
19 microinvasive cervical squamous cell carcinoma 10.2 CHGA SYP
20 early-onset parkinson disease 10.2 GHRL SYP
21 perineural angioma 10.2 CHGA SYP
22 pemphigus foliaceus 10.2 PPY SYP
23 breast mucoepidermoid carcinoma 10.2 POU5F1 SOX2 SYP
24 diffuse cutaneous mastocytosis 10.2 CHGA SYP
25 main bronchus cancer 10.2 CHGA SYP
26 atopic dermatitis 10.2 POU5F1 SOX2 SYP
27 gliofibroma 10.2 CHGA SYP
28 cavernous hemangioma of face 10.2 CHGA SYP
29 pneumothorax 10.2 POU5F1 SYP
30 adult botryoid rhabdomyosarcoma 10.2 CHGA SYP
31 superior vena cava syndrome 10.2 CHGA SYP
32 exudative glomerulonephritis 10.2 CHGA SYP
33 subendocardial myocardial infarction 10.2 POU5F1 SOX17 SOX2
34 fragile x-associated tremor/ataxia syndrome 10.2 CHGA SYP
35 hepatorenal syndrome 10.2 CHGA SYP
36 acalculous cholecystitis 10.2 CHGA SYP
37 urinary tract papillary transitional cell benign neoplasm 10.2 CHGA SOX2 SYP
38 piussan lenaerts mathieu syndrome 10.2 CHGA SYP
39 brain stem astrocytic neoplasm 10.1 CHGA SYP
40 anal squamous cell carcinoma 10.1 CHGA SYP
41 calcific tendinitis 10.1 CHGA SYP
42 malignant pleural solitary fibrous tumor 10.1 CHGA POU5F1 SOX2 SYP
43 nutritional optic neuropathy 10.1 GAST GHRL
44 autoimmune pancreatitis 10.1 CHGA GAST
45 secondary syphilis 10.1 CHGA GAST
46 brain edema 10.1 CHGA GAST
47 uterine corpus myxoid leiomyosarcoma 10.1 CHGA SYP
48 granulocytopenia 10.0 CHGA GAST
49 cherubism 10.0 GAST PPY
50 volkmann contracture 10.0 CHGA GAST

Graphical network of the top 20 diseases related to Functioning Pancreatic Endocrine Tumor:



Diseases related to Functioning Pancreatic Endocrine Tumor

Symptoms & Phenotypes for Functioning Pancreatic Endocrine Tumor

MGI Mouse Phenotypes related to Functioning Pancreatic Endocrine Tumor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 SOX2 SYP TOP2B FOXA2 GHRL NKX6-1
2 cellular MP:0005384 9.97 FOXA2 NEUROG3 NKX6-1 NKX6-2 POU5F1 PTF1A
3 digestive/alimentary MP:0005381 9.86 FOXA2 GAST GHRL NEUROG3 POU5F1 PTF1A
4 endocrine/exocrine gland MP:0005379 9.85 CHGA FOXA2 GAST GHRL NEUROG3 NKX6-1
5 mortality/aging MP:0010768 9.7 CHGA FOXA2 GAST NEUROG3 NKX6-1 NKX6-2
6 normal MP:0002873 9.32 SOX17 SOX2 SYP TOP2B FOXA2 GHRL

Drugs & Therapeutics for Functioning Pancreatic Endocrine Tumor

Drugs for Functioning Pancreatic Endocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
2 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
3 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
4 Fluorodeoxyglucose F18 Phase 4
5 Omega 3 Fatty Acid Nutraceutical Phase 4
6 arginine Nutraceutical Phase 4
7 glutamine Nutraceutical Phase 4
8
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
9
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
10
Somatostatin Approved Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
11
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
12
Heparin Approved, Investigational Phase 2, Phase 3 9005-49-6 772 46507594
13
Levoleucovorin Approved Phase 2, Phase 3 68538-85-2
14
Sunitinib Approved, Investigational Phase 3 341031-54-7, 557795-19-4 5329102
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 54575, 6560146 143
17 Anti-Infective Agents Phase 2, Phase 3,Phase 1
18 Antimetabolites Phase 2, Phase 3,Phase 1
19 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
20 Antiviral Agents Phase 2, Phase 3,Phase 1
21 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
22 Liver Extracts Phase 3,Phase 2,Phase 1
23 Hormone Antagonists Phase 3,Phase 1,Phase 2,Early Phase 1
24 Hormones Phase 3,Phase 1,Phase 2,Early Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2,Early Phase 1
26 Antidotes Phase 2, Phase 3
27 calcium heparin Phase 2, Phase 3
28 Hematinics Phase 2, Phase 3,Phase 1
29 Micronutrients Phase 2, Phase 3,Phase 1
30 Protective Agents Phase 2, Phase 3,Phase 1
31 Trace Elements Phase 2, Phase 3,Phase 1
32 Vitamin B Complex Phase 2, Phase 3,Phase 1
33 Vitamins Phase 2, Phase 3,Phase 1
34 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
35 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
36 Folate Nutraceutical Phase 2, Phase 3,Phase 1
37 Vitamin B9 Nutraceutical Phase 2, Phase 3,Phase 1
38
Menthol Approved Phase 2,Early Phase 1 2216-51-5 16666
39
Daclizumab Approved, Investigational Phase 1, Phase 2 152923-56-3
40
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
41
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
42
Exenatide Approved, Investigational Phase 1, Phase 2 141758-74-9 15991534
43
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
44
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492
45
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
46
Pantoprazole Approved Phase 2 102625-70-7 4679
47
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
48
Streptozocin Approved Phase 2 18883-66-4 29327
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3
50
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441

Interventional clinical trials:

(show top 50) (show all 96)
id Name Status NCT ID Phase
1 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4
2 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4
3 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
4 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
5 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
6 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Active, not recruiting NCT02238847 Phase 4
7 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
8 Evaluation of A New Digestive Reconstruction Procedure Following Pancreatoduodenectomy Unknown status NCT01931449 Phase 3
9 Chemotherapy With or Without Enoxaparin in Pancreatic Cancer Completed NCT00785421 Phase 2, Phase 3
10 Early Palliative Care on Quality of Life of Advanced Cancer Patients Completed NCT02988635 Phase 3
11 Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies Active, not recruiting NCT01401907 Phase 3
12 Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Not yet recruiting NCT02705651 Phase 3
13 A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3
14 Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer Unknown status NCT00082862 Phase 2
15 Evaluation of Preoperative Biliary Drainage Before Pancreatoduodenectomy Unknown status NCT01941342 Phase 2
16 Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression Unknown status NCT00566813 Phase 1, Phase 2
17 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2
18 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2
19 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer Completed NCT01396382 Phase 2
20 A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract. Completed NCT00448136 Phase 2
21 High Dose Somatostatin Analogues in Neuroendocrine Tumors Completed NCT00990535 Phase 2
22 Trial of Curcumin in Advanced Pancreatic Cancer Completed NCT00094445 Phase 2
23 Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer Completed NCT01547260 Phase 1, Phase 2
24 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2
25 EGF Ointment for Erlotinib Skin Lesion Completed NCT01593995 Phase 2
26 A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer Completed NCT00383149 Phase 2
27 Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation Completed NCT00789308 Phase 2
28 Exenatide and Metformin Therapy in Overweight Women With PCOS Completed NCT00344851 Phase 2
29 Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas (PC04) Recruiting NCT02598349 Phase 2
30 Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients Recruiting NCT02862015 Phase 2
31 A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas Recruiting NCT01838317 Phase 2
32 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Not yet recruiting NCT02923934 Phase 2
33 High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain Suspended NCT00637364 Phase 1, Phase 2
34 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2
35 HYPAZ: Hypertension Induced by Pazopanib Terminated NCT01392352 Phase 2
36 Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Terminated NCT00529113 Phase 1, Phase 2
37 Islet After Kidney Transplant for Type 1 Diabetes Withdrawn NCT00784966 Phase 1, Phase 2
38 Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant Withdrawn NCT00790439 Phase 2
39 Modification of the "Edmonton Protocol" to Allow for Successful Islet Transplantation From a Single Pancreas and Extension of the "Edmonton Protocol" to Kidney Transplant Recipients Unknown status NCT00021580 Phase 1
40 Cord Blood Infusion for Type 1 Diabetes Mellitus (T1DM) Unknown status NCT00989547 Phase 1
41 A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer Completed NCT01049880 Phase 1
42 ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer Completed NCT00056537 Phase 1
43 FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Completed NCT01413022 Phase 1
44 Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors Completed NCT00385177 Phase 1
45 Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs Completed NCT01263353 Phase 1
46 Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer Completed NCT00294203 Phase 1
47 Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors Completed NCT02262455 Phase 1
48 Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation With Gemcitabine, Sorafenib and Vorinostat in Resectable, Borderline Resectable or Unresectable Non-metastatic Pancreas Cancer Recruiting NCT02349867 Phase 1
49 Epidural Analgesia Use in Pancreatic Resections Recruiting NCT02681796 Phase 1
50 Natural Killer Cells and Bortezomib to Treat Cancer Recruiting NCT00720785 Phase 1

Search NIH Clinical Center for Functioning Pancreatic Endocrine Tumor

Genetic Tests for Functioning Pancreatic Endocrine Tumor

Anatomical Context for Functioning Pancreatic Endocrine Tumor

Publications for Functioning Pancreatic Endocrine Tumor

Articles related to Functioning Pancreatic Endocrine Tumor:

id Title Authors Year
1
Non-functioning pancreatic endocrine tumors: eleven-year experience in a single institute. ( 24965405 )
2014
2
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. ( 22261919 )
2012

Variations for Functioning Pancreatic Endocrine Tumor

Expression for Functioning Pancreatic Endocrine Tumor

Search GEO for disease gene expression data for Functioning Pancreatic Endocrine Tumor.

Pathways for Functioning Pancreatic Endocrine Tumor

GO Terms for Functioning Pancreatic Endocrine Tumor

Biological processes related to Functioning Pancreatic Endocrine Tumor according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 transcription from RNA polymerase II promoter GO:0006366 9.91 NEUROG3 NKX6-1 POU5F1 PTF1A SOX2
2 multicellular organism development GO:0007275 9.87 FOXA2 NEUROG3 NKX6-1 NKX6-2 POU5F1 PTF1A
3 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.85 NEUROG3 NKX6-1 NKX6-2 POU5F1 SOX17 SOX2
4 forebrain development GO:0030900 9.67 NEUROG3 SOX2 TOP2B
5 positive regulation of cell differentiation GO:0045597 9.61 NEUROG3 SOX17 SOX2
6 oligodendrocyte differentiation GO:0048709 9.57 NKX6-1 NKX6-2
7 pancreas development GO:0031016 9.56 NKX6-1 PTF1A
8 hindbrain development GO:0030902 9.55 NEUROG3 PTF1A
9 mRNA transcription from RNA polymerase II promoter GO:0042789 9.54 POU5F1 SOX17
10 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.5 FOXA2 NEUROG3 NKX6-1 POU5F1 PTF1A SOX17
11 endodermal cell fate specification GO:0001714 9.48 POU5F1 SOX2
12 positive regulation of glial cell differentiation GO:0045687 9.46 NKX6-1 NKX6-2
13 regulation of transcription from RNA polymerase II promoter involved in ventral spinal cord interneuron specification GO:0021913 9.4 NKX6-1 NKX6-2
14 regulation of transcription from RNA polymerase II promoter involved in spinal cord motor neuron fate specification GO:0021912 9.26 NKX6-1 NKX6-2
15 negative regulation of glial cell differentiation GO:0045686 9.16 NKX6-1 NKX6-2
16 endocrine pancreas development GO:0031018 8.92 FOXA2 NEUROG3 NKX6-1 NKX6-2
17 regulation of transcription, DNA-templated GO:0006355 10.13 FOXA2 NEUROG3 NKX6-1 NKX6-2 POU5F1 PTF1A

Molecular functions related to Functioning Pancreatic Endocrine Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.7 FOXA2 NEUROG3 NKX6-1 NKX6-2 POU5F1 SOX17
2 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.67 FOXA2 NEUROG3 NKX6-1 NKX6-2
3 RNA polymerase II transcription factor activity, sequence-specific DNA binding GO:0000981 9.61 FOXA2 POU5F1 SOX17
4 DNA binding GO:0003677 9.61 FOXA2 NEUROG3 NKX6-1 NKX6-2 POU5F1 PTF1A
5 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001078 9.58 NEUROG3 NKX6-1 NKX6-2
6 hormone activity GO:0005179 9.43 GAST GHRL PPY
7 miRNA binding GO:0035198 9.32 POU5F1 SOX2
8 sequence-specific DNA binding GO:0043565 9.17 FOXA2 NKX6-1 NKX6-2 POU5F1 PTF1A SOX17

Sources for Functioning Pancreatic Endocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....